Latest news
Roche’s Nearly $2B Atavistik Bet Goes After Cardiometabolic Targets Other Drugs Struggle to Reach
Roche is paying Atavistik Bio $70 million upfront in a discovery partnership that could generate another $1.9 billion in milestones, plus royalties. The companies will use Atavistik’s allosteric discovery platform to pursue undisclosed cardiovascular, renal and metabolic targets, extending Roche’s rapidly expanding CVRM strategy into earlier and potentially harder-to-drug biology.
Lenacapavir Turns HIV Prevention Into an Access Stress Test
WHO’s AMR Plan Turns Access Into Preparedness
Diabetic Eye Screening Is Becoming Risk-Based
Abu Dhabi Puts Rare Eye Gene Therapy on the Regional Map
AI Eye Screening Has an Image Quality Problem
AI Retinal Screening Moves Into the Diabetes Clinic
India Turns AI Eye Screening Into Public-Health Infrastructure
Geographic Atrophy Forces Europe to Define Meaningful Vision Benefit
Eye Health Moves From Charity Case to Investment Case
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.